Figure 4

VEGFR2 inhibition with CT-322 reduces microvessel density in a syngeneic model of pancreatic cancer. Frozen sections of tumors from mice treated with vehicle alone (Control), CT-322, gemcitabine (GEM), or the combination of CT-322 + gemcitabine were evaluated for microvessel density by immunohistochemistry using MECA-32. Representative images of MECA-32 immunohistochemistry are displayed along with the mean (+/- SEM) number of blood vessels/field (total magnification, 200×). Microvessel density in Pan02 tumors from mice treated with CT-322 monotherapy was reduced compared to tumors from control-treated animals (control, 70.0 ± 3.6; CT-322, 52.6 ± 2.3; 3 tumors per group, at least 5 fields per tumor; *, p < 0.001 vs. control). Two representative pictures from each group are shown.